UNSPSC 51282124: Carumonam sodium

This classification denotes a beta-lactam antibiotic with the molecular structure C12H12N6O10S2.2NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, B4J4M4939D chemically known as acetic acid, (((2-((2-(((aminocarbonyl)oxy)methyl)-4-oxo-1-sulfo-3-azetidinyl)amino)-1-(2-amino-4-thiazolyl)-2-oxoethyliden)amino)oxy)-, disodium salt, (2s-(2.alpha.,3.alpha.(z)))-, but more commonly known as carumonam sodium, which bears US NIH Compound Identifier 9568618.

UNSPSC 51282124 Carumonam sodium is a Commodity code that, based on recent state and local solicitations, encompasses pharmaceutical products and medical supplies procured by health agencies, fire departments, and cooperative purchasing bodies. State and local governments are buying naloxone, injectable pharmaceuticals, over-the-counter medications, and related medical consumables through this code. The issuing bodies span county health departments, state health and human services commissions, city fire rescue divisions, and multistate cooperative purchasing alliances. Seminole County, Florida; the Texas Health and Human Services Commission; the City of Tampa; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP, serving Minnesota and Oregon) have posted recent opportunities under or aligned with pharmaceutical and medical-supply procurement.

Recent activity concentrates in Florida, Texas, and the Upper Midwest. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023 (note: the bid opening date conflicts with the posted date; the actual response window and delivery timeline are ambiguous in the source). The City of Tampa posted IFB 26P00145 in March 2026 for medical and first aid supplies including respiratory equipment, cardiac electrodes, and consumables for the Fire Department Rescue Division, with an estimated contract value of $700,000 and a small-local-business-enterprise (SLBE) set-aside of 5 percent discount (not to exceed $10,000). The Texas HHS Commission issued RFI HHS0017013 in April 2026 to gather vendor capability information on direct-to-manufacturer prescription programs. MMCAP posted RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with a two-year contract term and performance penalties ranging from $200 to $1,500 per violation.